Watchlist Price Alert

Equillium Inc. (EQ)

NASDAQ: EQ · Real-Time Price · USD

0.37

-0.01 (-2.63%)

At close: Jun 09, 2025, 3:59 PM

-2.63% (1D)

Bid	0.36
Market Cap	13.31M
Revenue (ttm)	30.41M
Net Income (ttm)	-13.99M
EPS (ttm)	-0.39
PE Ratio (ttm)	-0.96
Forward PE	-0.33
Analyst	Hold

Ask	0.4
Volume	21,113
Avg. Volume (20D)	103,676
Open	0.39
Previous Close	0.38
Day's Range	0.36 - 0.39
52-Week Range	0.34 - 1.50
Beta	1.95

About EQ

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EQ

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EQ stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-2.08%

Equillium shares are trading lower after the compa... Unlock content with Pro Subscription

3 months ago

-16.93%

Equillium shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered the price target from $3 to $1.

News

1 month ago · businesswire.com

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

2 months ago · zacks.com

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio...

3 months ago · benzinga.com

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD)...

3 months ago · businesswire.com

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...